The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR/ARHP Annual Meeting 2012: Risk of Immunosuppression from Rheumatic Disease Therapies Poses Challenge for Rheumatologists

ACR/ARHP Annual Meeting 2012: Risk of Immunosuppression from Rheumatic Disease Therapies Poses Challenge for Rheumatologists

March 1, 2013 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Under a high magnification of 15549x, this colorized scanning electron micrograph (SEM) depicted some of the ultrastructural details seen in the cell wall configuration of a number of Gram-positive Mycobacterium tuberculosis bacteria. As an obligate aerobic organism M. tuberculosis can only survive in an environment containing oxygen.

WASHINGTON, D.C.—Widely used therapies for rheumatic diseases can be immunosuppressive, raising the risk of tuberculosis (TB) and other serious infectious diseases in these patients. If infected, treatment decisions become more complicated, said Neil Ampel, MD, professor of medicine at the University of Arizona School of Medicine in Tucson, in a session titled, “Fungal Infections and Tuberculosis in Patients with Rheumatologic Disease,” at the 2012 ACR/ARHP Annual Meeting, held here November 9–14. [Editor’s Note: This session was recorded and is available via ACR Session Select at www.rheumatology.org.]

You Might Also Like
  • ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines
  • ACR/ARHP Annual Meeting 2012: Understanding Pain Signals May Pave Path to More Effective Therapies
  • 2014 ACR/ARHP Annual Meeting: Super Proteins Eyed in Therapies for Rheumatic Diseases
Explore This Issue
March 2013
Also By This Author
  • Diversity: From Concepts to Outcomes

People with rheumatic diseases may be at increased risk of developing mycobacterial infections like TB or fungal infections such as histoplasmosis or coccidioidomycosis, among others, Dr. Ampel said. Glucocorticoids may raise the risk of developing granulomatous diseases almost threefold, even at doses of 15 mg daily or less, he said. Biologic response modifiers (BRMs) also may increase infection risk, though they vary, he added. Methotrexate has a lower risk.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The cytokine tumor necrosis factor–alpha (TNFα) is critical for the formation of granulomata, Dr. Ampel said. Drugs like etanercept, infliximab, adalimumab, and certoluzimab pegol inhibit this cytokine, increasing susceptibility to certain infections. “It makes good sense that by blocking TNFα, this can have a salutatory effect on the rheumatic disease, but you do increase the risk of infection because they inhibit cellular immunity,” he said. Etanercept is less immunosuppressive than monoclonal antibodies, which bind to both TNFα and the cells that produce it, blocking the cellular immune response, he added.

After diagnosis of an infection, rheumatologists may manage the patient by first treating the offending pathogen, stopping BRMs, and reducing or stopping methotrexate or glucocorticoids. Once the infection is under control, it is often appropriate to restart BRM therapy, Dr. Ampel said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Tracking TB

TB is in dramatic decline in the U.S., with fewer than 11,000 cases reported in 2011. It is important to know the patient’s history to determine risk, he said. Patients born outside the country, particularly in Asia, are more likely to have TB. People with human immunodeficiency virus (HIV) infection are also at increased risk. Tuberculosis is rarely diagnosed in its primary stage, he added. If infected, patients’ disease may enter a latent stage and then later reactivate.

Pages: 1 2 3 | Single Page

Filed Under: Meeting Reports Tagged With: ACR/ARHP Annual Meeting, Infection, Rheumatic Disease, Treatment, TuberculosisIssue: March 2013

You Might Also Like:
  • ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines
  • ACR/ARHP Annual Meeting 2012: Understanding Pain Signals May Pave Path to More Effective Therapies
  • 2014 ACR/ARHP Annual Meeting: Super Proteins Eyed in Therapies for Rheumatic Diseases
  • ACR/ARHP Annual Meeting 2012: New Research Delves Into the Risk of Comorbidities for Patients with Lupus

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)